Intuitive Surgical Today
Surgical intuitive
As of 10/13/2025 at 04:00 PM ET
- 52 week range
- $425.00
▼
$616.00
- P/E ratio
- 60.77
- Price target
- $584.76
Intuitive Surgical Company Nasdaq: ISRG It is entering a potential breakout window as it heads into its next earnings report on October 21, 2025. A flurry of recent developments have improved the outlook and set the stage for a potential rally leading up to — or after — the announcement.
With new FDA approvals and the green light for European expansion, Intuitive Surgical now has access to a much larger and more actionable customer base. These developments have significantly expanded its addressable market and could lead to increased adoption of its systems both in the United States and abroad.
This broader reach should start to show in improved earnings results over the coming quarters. As is often the case in the healthcare sector, regulatory developments play a pivotal role in shaping investor sentiment.
It is worth noting that there is growing speculation that major regulations may be passed soon, especially in light of recent buying activity from several members of the US Congress – a sign that has not gone unnoticed by the market. As a result, investors are now assigning a premium rating to the company, reflecting heightened expectations for future growth. For individual investors, this is an opportunity worth serious consideration.
Why intuitive surgery can win
Intuitive Surgical is developing AI-based robots to perform surgical procedures, enabling medical professionals to perform these procedures remotely with precision and precision. Given the nature of this company’s industry, it is inherently surrounded by moats that neither competition nor the adoption of artificial intelligence can penetrate.
This may be the reason why the markets view this company as a standout, but there is a lot more behind it. One of these drivers is the last FDA approval For Intuitive Surgical’s Da Vinci 5 software features, which will facilitate further adoption of this technology and enable remote surgical procedures assisted by robotics and artificial intelligence.
Second, trials of the ionic endoluminal system have now been approved throughout Europe and the United States, Which involves more than 2000 topics. These studies increase the likelihood that this company will begin reporting more diversified revenue streams and rapid growth, boosting its valuation.
Despite these bullish factors, the stock is trading at just 70% of its 52-week high (in bear market territory), creating a more attractive risk-reward ratio for new and existing shareholders. Some of these new contributors include members of Congress who may or may not possess valuable information regarding future FDA approvals and developments.
Markwayne Mullin bought up to $100,000 at an average price of $443.99 per share, or Ro Khanna who bought up to $15,000 at an average price of $466.66. These purchases were made in September 2025, just one month before the company releases its quarterly results, which will likely include some positive guidance given recent FDA approvals and European expansion.
What do markets think about intuitive surgical stocks?
Intuitive Surgical Stock Forecast Today
$584.76
34.20% upModerate purchase
Based on 22 analyst ratings
| Current price | $435.73 |
|---|---|
| High expectations | $700.00 |
| Average expectations | $584.76 |
| Low expectations | $440.00 |
Details intuitive surgical inventory forecasts
The most obvious way investors can measure sentiment is through valuation multiples. In the case of Intuitive Surgical, the price-to-earnings ratio of 59.9x indicates a high favorability for this stock. This multiple requires a large premium to the medical instruments industry, just 26.3x, and there must be a reason why markets are willing to overpay here.
Wall Street analysts’ consensus target price for the stock is $589.43 per share, implying a potential upside of 37.2% from the current trading price, without taking into account the potential financial benefits that may arise from recent developments.
Despite these tailwinds, the company reported net earnings per share (EPS) of $2.19 in its most recent quarterly results, 13% above the MarketBeat consensus of $1.93. This business can succeed for several fundamental reasons, but it also goes beyond the Intuitive Surgical business.
the Healthcare Select Sector SPDR Fund NYSEARCA: XLV It has underperformed the broader S&P 500 by about 22% over the past 12 months, representing the widest spread in more than a decade. This means that healthcare stocks, in general, are being squeezed in terms of valuations and price action.
If the recovery extends to the entire sector, Intuitive Surgical could amplify its bullish fundamentals and accelerate its rally higher alongside other industry peers, thus creating a great risk-reward setup.
Before you consider Intuitive Surgical, you’ll want to hear this.
MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and Intuitive Surgical wasn’t on the list.
While Intuitive Surgical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View the five stocks here
Discover the eternal value of gold with our exclusive 2025 Gold Forecast. Find out why gold remains the ultimate investment for protecting wealth from inflation, economic shifts and global uncertainties. Whether you are planning for future generations or looking for reliable assets in turbulent times, this report is your essential guide to making informed decisions.
